Primary Recommendation

Dechra Pharmaceuticals - US launch of Vetoryl to boost profits

February 2010

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

The fact that specialist retailer Pets At Home, which is being groomed for a spring flotation, has just announced a 16% rise in sales suggests that we are still a nation of pet lovers even when cash is scarce. One company benefiting from this trend is FTSE 250 listed, Dechra Pharmaceuticals.Dechra’s main success drivers are its own brand pharmaceutical products for cats and dogs. The key product which encapsulates what is happening at Dechra is Vetoryl, for treating Cushings disease. Launched a few years ago in Europe it has already grown annual sales to £8m and will soon be launched into the US - a ten times bigger market. The strong performance on the pharma side has been augmented by an equally strong performance fr ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Craneware - Billing software firm enjoying quick-fire growth

Dechra Pharmaceuticals (November 2010)

Dechra Pharmaceuticals (November 2008)

Dechra Pharmaceuticals - US blockbuster potential for key drug (August 2008)

Dechra Pharmaceuticals - Impending US drug approval could herald profit surge (April 2007)

Dechra Pharmaceuticals - Gains approach Â£1 per share (November 2005)

Dechra Pharmaceuticals (April 2005)

Dechra Pharmaceuticals - Positive AGM (December 2004)

Dechra Pharmaceuticals - New animal drug could be blockbuster (October 2004)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X